News Center

Ambrx Appoints Olivia Ware and Katrin Rupalla to its Board of Directors

Apr 14, 2021 | News Press Releases
SAN DIEGO, Calif., April 14, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of...

Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer

Mar 17, 2021 | News Press Releases
SAN DIEGO, Calif., March 17, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced that the U.S. Food and...

Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Feb 23, 2021 | News Press Releases
SAN DIEGO, Calif., February 23, 2021 – Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet...

FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer

Jan 4, 2021 | News Press Releases
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or...

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

Dec 10, 2020 | News Press Releases
• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU • Multiple Global Phase...